Taylor Frigon Capital Management LLC Decreases Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Taylor Frigon Capital Management LLC lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) by 5.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,421 shares of the company’s stock after selling 436 shares during the quarter. IDEXX Laboratories comprises about 1.7% of Taylor Frigon Capital Management LLC’s holdings, making the stock its 17th largest holding. Taylor Frigon Capital Management LLC’s holdings in IDEXX Laboratories were worth $3,027,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ronald Blue Trust Inc. purchased a new position in IDEXX Laboratories in the 2nd quarter worth approximately $34,000. Carolinas Wealth Consulting LLC purchased a new position in IDEXX Laboratories in the 1st quarter worth approximately $39,000. Riverview Trust Co boosted its holdings in IDEXX Laboratories by 202.8% in the 3rd quarter. Riverview Trust Co now owns 109 shares of the company’s stock worth $36,000 after acquiring an additional 73 shares during the period. Atlas Capital Advisors LLC purchased a new position in IDEXX Laboratories in the 2nd quarter worth approximately $44,000. Finally, General Partner Inc. purchased a new position in IDEXX Laboratories in the 4th quarter worth approximately $53,000. Hedge funds and other institutional investors own 87.90% of the company’s stock.

Insider Activity at IDEXX Laboratories

In related news, SVP Kathy V. Turner sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 14th. The stock was sold at an average price of $504.59, for a total transaction of $1,009,180.00. Following the sale, the senior vice president now directly owns 7,380 shares of the company’s stock, valued at approximately $3,723,874.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, SVP Kathy V. Turner sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 14th. The stock was sold at an average price of $504.59, for a total transaction of $1,009,180.00. Following the sale, the senior vice president now directly owns 7,380 shares of the company’s stock, valued at approximately $3,723,874.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Kathy V. Turner sold 1,000 shares of the stock in a transaction on Thursday, February 9th. The stock was sold at an average price of $505.04, for a total value of $505,040.00. Following the completion of the sale, the senior vice president now directly owns 6,941 shares in the company, valued at $3,505,482.64. The disclosure for this sale can be found here. Corporate insiders own 2.06% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock traded down $2.75 on Friday, hitting $471.36. 731,245 shares of the stock traded hands, compared to its average volume of 362,561. The company has a debt-to-equity ratio of 1.14, a current ratio of 0.89 and a quick ratio of 0.59. The company has a market capitalization of $39.08 billion, a PE ratio of 58.70, a PEG ratio of 2.75 and a beta of 1.18. IDEXX Laboratories, Inc. has a 1-year low of $317.06 and a 1-year high of $560.92. The company’s fifty day moving average is $481.48 and its 200 day moving average is $415.20.

IDEXX Laboratories (NASDAQ:IDXX – Get Rating) last posted its quarterly earnings results on Monday, February 6th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.13. The business had revenue of $828.60 million for the quarter, compared to analyst estimates of $820.91 million. IDEXX Laboratories had a return on equity of 124.51% and a net margin of 20.17%. The business’s revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.89 EPS. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 9.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on IDXX shares. StockNews.com started coverage on IDEXX Laboratories in a report on Thursday. They issued a “buy” rating for the company. Barclays increased their target price on IDEXX Laboratories from $582.00 to $590.00 and gave the company an “overweight” rating in a research note on Wednesday, February 8th. Atlantic Securities increased their target price on IDEXX Laboratories from $470.00 to $600.00 and gave the company an “overweight” rating in a research note on Tuesday, February 7th. TheStreet upgraded IDEXX Laboratories from a “c+” rating to a “b-” rating in a research note on Friday, November 25th. Finally, JPMorgan Chase & Co. increased their target price on IDEXX Laboratories from $525.00 to $550.00 and gave the company an “overweight” rating in a research note on Tuesday, February 7th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $514.75.

About IDEXX Laboratories

(Get Rating)

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other.